TCI Revolutionizes Weight Management with Breakthrough GLP-1 Innovation

Contributed by: PR Newswire

Tags

TCI-GLP-1

More Like This

PR Newswire associated0

Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks

PR Newswire associated0

Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions

PR Newswire associated0

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

PR Newswire associated0

GLP-1 DRUG LIRAGLUTIDE MAY PROTECT AGAINST DEMENTIA

PR Newswire associated0

Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial

PR Newswire associated0

Hanmi Unveils Novel Obesity Drug 'HM17321' : A Game-Changer in Overcoming GLP-1-Associated Muscle Loss

PR Newswire associated0

Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing